Immunoadsorption in steroid-refractory multiple sclerosis: Clinical experience in 60 patients

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 167-173

  Heigl, Franz ^a   Hettich, Reinhard ^a   Arendt, Rainer ^b   Durner, Joachim ^c   Koehler, Jürgen ^d   Mauch, Erich ^e  

^a Dres Heigl Hettich and Partner Medizinisches Versorgungszentrum Kempten Allgäu   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Fachklinik Ichenhausen   (Germany)

^d Marianne Strauss Hospital   (Germany)

^e Dietenbronn GmbH   (Germany)

Author keywords

Immunoadsorption; Multiple sclerosis; Steroid refractory relapse

Indexed keywords

TRYPTOPHAN;

ADULT; APPLICATION SITE DISCOMFORT; ARTICLE; CENTRAL VENOUS CATHETER; CLINICAL STUDY; DETERIORATION; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEMATOMA; HUMAN; IMMUNOADSORPTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; OPTIC NEURITIS; OUTCOME ASSESSMENT; PERIPHERAL VEIN; PLASMA VOLUME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPASTIC PARESIS; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR ACCESS; VERTIGO; VISUAL ACUITY;

ABSORPTION; ADULT; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; AUTOIMMUNITY; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; DISABILITY EVALUATION; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSORBENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; STEROIDS; TIME FACTORS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84872852405     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.025     Document Type: Article

References (29)

1. Weinshenker B.G. The natural history of multiple sclerosis: update 1998. Semin Neurol 1998, 18:301-307.
2. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955.
3. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717.
4. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG), Rieckmann P. Immunmodulatorische Stufentherapie der Multiplen Sklerose. Aktuelle Therapieempfehlungen (September 2006). Nervenarzt 2006, 77:1506-1518.
5. Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H., Toyka K.V., Rieckmann P., et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008, 255:1449-1463.
6. Guidelines for diagnosis and therapy in neurology (Leitlinien für die Diagnostik und Therapie in der Neurologie) 2008, German Society for Neurology, Georg Thieme Publishers, Stuttgart. http://www.dgn.de, H.C. Diener, N. Putzki (Eds.).
7. Weinshenker B.G., O'Brien P.C., Petterson T.M., et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878-886.
8. Ruprecht K., Klinker E., Dintelmann T., Rieckmann P., Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004, 63:1081-1083.
9. Schilling S., Linker R.A., König F.B., et al. Plasmaaustausch bei steroidresistenten Multiple-Sklerose-Schüben - Klinische Erfahrungen an 16 Patienten. Nervenarzt 2006, 77:430-438.
10. Trebst C., Reising A., Kielstein J.T., Hafer C., Stangel M. Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2009, 28:108-115.
11. Schröder A., Fischer M., Meyer C., et al. Plasmapherese in der Eskalationstherapie der Multiplen Sklerose: Verlaufsbeobachtung an 35 Patienten. Akt Neurol 2009, 36:105-110.
12. Keegan M., König F., McClelland R., et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005, 366:579-582.
13. Trebst C., Bronzlik P., Kielstein J.T., Schmidt B.M., Stangel M. Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2012, 33:1-6.
14. Schimrigk S., Adibi I., Eberl A., Selka I., et al. Immunadsorption zur Eskalation der Schubtherapie bei Multipler Sklerose. Akt Neurol 2012, 39:174-179.
15. Koziolek M., Tampe D., Bähr M., et al. Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflammation 2012, 9:80.
16. Seta T., Nagayama H., Katsura K., et al. Factors influencing outcome in Guillain-Barré syndrome: comparison of plasma adsorption against other treatments. Clin Neurol Neurosurg 2005, 107:491-496.
17. Galldiks N., Dohmen C., Neveling M., Fink G.R., Haupt W.F. Selective immune adsorption treatment of severe Guillain Barré Syndrome in the intensive care unit. Neurocrit Care 2009, 11:317-321.
18. Köhler W., Bucka C., Klingel R. A randomised and controlled clinical study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 2011, 26:347-355.
19. Gold R., Krenzer M., Kliniker E., Mansouri B., et al. Efficacy and safety of immunoadsorption vs plasmapheresis vs combination for treatment of myasthenic crisis: comparative retrospective study on 72 patients. Neurology 2008, 70(Suppl. 1):A427.
20. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33(11):1444-1452.
21. Mauch E., Zwanzger J., Hettich R., Fassbender C., Klingel R., Heigl F. Immunadsorption bei steroidrefraktärem Schub der Multiplen Sklerose. Nervenarzt 2011, 82(12):1590-1595.
22. Klingel R., Heibges A., Fassbender C. Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives. Atheroscler Suppl 2009, 10(5):129-132.
23. Leech S., Kirk J., Plumb J., McQuaid S. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 2007, 33(1):86-98.
24. Grob D., Simpson D., Mitsumoto H., et al. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995, 45:338-344.
25. Bucka C., Köhler W., Hertel G., et al. Immunadsorption bei Myasthenia gravis. Wirkungsweise, immunologische Parameter und klinischer Verlauf. Akt Neurol 1993, 20:207-213.
26. Hosokawa S., Oyamaguchi A., Yoshida O. Successful immunoadsorption with membrane plasmapheresis for multiple sclerosis. ASAIO Trans 1989, 35:576-577.
27. Schneidewind-Müller J.M., Winkler R.E., Tiess M., Müller W., Ramlow W. Changes in lymphocytic cluster distribution during extracorporeal immunoadsorption. Artif Organs 2002, 26(2):140-144.
28. Hartung H.P. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009, 8:28-31.
29. Schmaldienst S., Jansen M., Hollstein U., et al. Treatment of systemic lupus erythematosus by immunoadsorption in a patient suffering from tuberculosis. Am J Kidney Dis 2002, 39(2):415-418.